BIIB:NGS-Biogen Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 141.6

Change

+0.70 (+0.50)%

Market Cap

USD 69.21B

Volume

1.83M

Analyst Target

USD 305.39
Analyst Rating

ducovest Verdict
Created with Highstock 5.0.6

Bullish

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
BIIB QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-24 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-1.04 (-1.40%)

USD 240.59B
AMGN Amgen Inc

-7.52 (-2.39%)

USD 162.78B
SNY Sanofi ADR

-0.48 (-0.86%)

USD 148.55B
GILD Gilead Sciences Inc

+1.15 (+1.08%)

USD 142.46B
GRFS Grifols SA ADR

-0.20 (-2.58%)

USD 7.13B
AMRN Amarin Corporation PLC

-0.01 (-1.18%)

USD 0.19B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.01 (-0.81%)

USD 0.02B
SCLX Scilex Holding Company

-0.03 (-9.71%)

N/A
SCLXW Scilex Holding Company

+0.04 (+33.64%)

N/A

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 6.12 % 0.95 %

+0.64 (+0.42%)

USD 3.28M
IBRN iShares Trust - iShares N.. 4.19 % 0.00 %

-0.40 (0.42%)

USD 3.90M
BTEC:SW iShares Nasdaq US Biotech.. 3.51 % 0.00 %

-0.08 (0.42%)

N/A
BBH VanEck Biotech ETF 3.07 % 0.35 %

-2.23 (0.42%)

USD 0.40B
MRND 2.44 % 0.00 %

N/A

N/A
IBB iShares Biotechnology ETF 2.05 % 0.47 %

-2.34 (0.42%)

USD 6.00B
SAGP The Advisorsa Inner Circl.. 1.97 % 0.00 %

+0.13 (+0.42%)

USD 0.04B
BIB ProShares Ultra Nasdaq Bi.. 1.49 % 0.95 %

-1.91 (0.42%)

USD 0.06B
GVLU Tidal ETF Trust 0.51 % 0.00 %

-0.10 (0.42%)

USD 0.18B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

+0.07 (+0.42%)

USD 34.09B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

+0.03 (+0.42%)

USD 8.52B
FLAG 0.00 % 1.52 %

N/A

N/A
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.83 (0.42%)

USD 1.01B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.08 (0.42%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.08 (0.42%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.02 (0.42%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.08 (0.42%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-1.74 (0.42%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-0.20 (0.42%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.05 (0.42%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-207.50 (0.42%)

N/A
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-1.58 (0.42%)

USD 0.01B
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

+0.37 (+0.42%)

N/A
MVUS:PA 0.00 % 0.00 %

N/A

N/A
SPMV:PA 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.10 (0.42%)

USD 0.52B
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

-1.90 (0.42%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.08 (0.42%)

USD 0.52B
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-1.75 (0.42%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.39 (0.42%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.40% 30% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.40% 30% F 41% F
Trailing 12 Months  
Capital Gain -34.65% 40% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.65% 40% F 28% F
Trailing 5 Years  
Capital Gain -50.31% 43% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.31% 43% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -6.12% 60% D- 26% F
Dividend Return -6.12% 60% D- 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.44% 50% F 68% D+
Risk Adjusted Return -23.15% 50% F 23% F
Market Capitalization 69.21B 50% F 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 100% 64%
Price/Book Ratio 1.23 75% 63%
Price / Cash Flow Ratio 7.15 75% 36%
Price/Free Cash Flow Ratio 8.77 75% 38%
Management Effectiveness  
Return on Equity 10.36% 75% 78%
Return on Invested Capital 22.15% 100% 85%
Return on Assets 5.29% 63% 85%
Debt to Equity Ratio 27.20% 80% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector